BofA downgrades Doximity (DOCS) to Underperform, slashing the price target to $20 amid soft pharma ad demand and AI execution risks.

Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrades, and initiations on analyst ratings page.

BofA downgrades Doximity (DOCS) to Underperform, slashing the price target to $20 amid soft pharma ad demand and AI execution risks.